Arcutis Biotherapeutics' Zoryve drives revenue growth and nears cash flow positivity, yet high valuation warrants a Hold ...
Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.
Organon a déclaré mardi avoir acquis de Biogen les droits réglementaires et commerciaux de Tofidence pour perfusion ...
Shanghai Henlius Biotech, Inc. et Organon ont annoncé aujourd’hui que l’Agence européenne des médicaments a validé la demande ...
If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...
“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a ...
First in class In May, the U.S. Food and Drug Administration approved Vtama (tapinarof) cream, an aryl hydrocarbon receptor agonist and the first FDA-approved steroid-free topical medication in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback